Label Image (Lbl500905760)
Levetiracetam
Product Images NDC 50090-5760
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-5760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
This is a figure (Figure 1) depicting the Responder Rate in Study 1 with a reduction of 250% from baseline. It shows a graph with percentages ranging from 0% to 39.6%, and two different treatments, Leviaseam 100 and Leviaseam 000, both of which are statistically significant versus placebo.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This is a figure from a medical study, showing the responder rate (250% reduction from baseline) in Study 2 period A. The figure displays the percentage of patients who responded to the treatment on the Y-axis, ranging from 0% to 40%. The X-axis shows the three groups of patients: placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The asterisk (*) indicates that the difference between the groups taking Levetiracetam 2000 mg/day and placebo was statistically significant.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a statistical figure from Study 3 showing the responder rate (>50% reduction from baseline) for a certain treatment. The placebo group (with 104 individuals) had a responder rate of 14.4%, while the group treated with 3000 mg/day of Levetiracetam (with 180 individuals) had a responder rate of 45%, which is considered statistically significant compared to the placebo group.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
The text describes a figure (Figure 4) that shows the responder rate in Study 4 where the percentage of reduction from baseline is 250%. There are two bars in the figure representing the placebo (N=97) and Levetiracetam (N=101) groups. The Levetiracetam group had a statistically significant result when compared to the placebo group. The text does not provide any additional information.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The figure shows the Responder Rate for patients between 1 month to less than 4 years old, with a reduction of over 50% from the baseline in Study 5. The percentage of responders is 190.6% for those treated with Lovetracatam and 0% for those who received placebo. Lovetracatam showed a statistically significant improvement compared to placebo.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The image shows the responder rate for PGTC seizure frequency per week in Study 7, indicating that Levetiracetam was statistically significant versus placebo with a 250% Reduction from Baseline. The graph shows that 72.2% of patients in the Levetiracetam group had a 50% or higher reduction in seizure frequency, compared to 45.2% in the placebo group. The image also shows the number of patients in each group and the percentage of responders.*
Chemical Structure (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
